Fig. 4.
Reduction of doxorubicin- or OKT3-induced apoptosis by Fab anti-CD95 antibody fragments or anti-CD95L antibody. CD3+ H9 cells were treated with 0.1 μg/mL doxorubicin (A) or CD3+ or CD3-H9 cells were incubated for 6 hours in 75 cm2 flasks precoated with 100 μg/mL OKT3 (B) for 24 hours or 48 hours in the absence (black bars) or presence (white bars) of 50 μg/mL Fab anti-CD95 antibody fragments or 100 μg/mL anti-CD95L antibody Nok-1. Apoptosis was determined as described in Figure 1.
